Table 1.
Clinical‐anthropometric characteristics, incretin and adipocytokine patterns in 96 patients with type 2 diabetes
| Clinical‐anthropometric characteristics | n (%) |
|---|---|
| Women | 51 (53.1) |
| Men | 45 (46.9) |
| Mean ± SD | |
|---|---|
| Age (years) | 62.40 ± 6.36 |
| Duration of disease (months) | 4.41 ± 1.66 |
| BMI (kg/m2) | 29.29 ± 4.65 |
| Waist circumference (cm) | 102.08 ± 11.31 |
| Hip circumference (cm) | 107.23 ± 10.28 |
| Waist‐to‐hip ratio | 0.95 ± 0.08 |
| Body Adiposity Index | 33.94 ± 6.47 |
| Visceral Adiposity Index | 2.28 ± 1.33 |
| HbA1c | |
| % | 6.92 ± 0.62 |
| mmol/mol | 52 ± 6.80 |
| HOMA‐IR | 3.08 ± 3.22 |
| Fasting insulin (pmol/L) | 64.32 ± 67.26 |
| Fasting C‐peptide (nmol/L) | 0.15 ± 0.15 |
| Fasting glucagon (ng/L) | 215.28 ± 68.08 |
| Urinary albumin‐to‐creatinine ratio (mg/g) | 16.69 ± 38.10 |
| Fasting lipids | |
| Total cholesterol (mmol/L) | 4.58 ± 0.85 |
| HDL cholesterol (mmol/L) | 1.25 ± 0.32 |
| LDL cholesterol (mmol/L) | 2.76 ± 0.84 |
| Triglycerides (mmol/L) | 1.41 ± 0.56 |
| NEFA (mmol/L) | 0.46 ± 0.27 |
| Fasting incretins | |
| GLP‐1 (pmol/L) | 5.92 ± 1.96 |
| GIP (pmol/L) | 16.56 ± 19.01 |
| Ghrelin (pmol/L) | 30.99 ± 8.74 |
| Fasting adipocytokines | |
| Leptin (ng/dL) | 8.83 ± 10.45 |
| sOb‐R (ng/mL) | 21.70 ± 6.56 |
| Leptin/sOb‐R ratio | 0.55 ± 0.88 |
| Adiponectin (μg/mL) | 11.75 ± 12.94 |
| Visfatin (ng/mL) | 0.62 ± 0.52 |
| Resistin (ng/mL) | 4.01 ± 4.68 |
BMI, body mass index; GIP, glucose‐dependent insulinotropic polypeptide; GLP‐1, glucagon‐like peptide‐1; HbA1c, glycated hemoglobin; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model addessment of insulin resistance; LDL, low‐density lipoprotein; NEFA, non‐esterified fatty acids; SD, standard deviation; sOB‐R, soluble leptin receptor.